Mglur5 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about this protein. See the content below for detailed information.
The mGluR5 protein is a class C G-protein coupled receptor consisting of three main domains:
mGluR5 is a Group I metabotropic glutamate receptor that activates PLC signaling and plays roles in learning, memory, and pain perception. It is linked to Fragile X syndrome and Alzheimer's disease.
The metabotropic glutamate receptors transduce signals through G-proteins:
Alzheimer's Disease: Dysregulated mGluR signaling contributes to:
Parkinson's Disease: Target for therapeutic intervention in:
Other Disorders: Schizophrenia, epilepsy, anxiety, Fragile X syndrome
Positive Allosteric Modulators (PAMs)
Negative Allosteric Modulators (NAMs)
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022. DOI: 10.1146/annurev-pharmtox-052120-013257
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for neurodegenerative disorders." Neuropharmacology. 2023. DOI: 10.1016/j.neuropharm.2022.109256
Dorostkar MM, et al. "Metabotropic glutamate receptor modulation in Alzheimer's disease." Alzheimers Res Ther. 2021. DOI: 10.1186/s13195-021-00876-5
The study of Mglur5 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Conn PJ, et al. "Metabotropic glutamate receptors: physiology, pharmacology, and disease." Annu Rev Pharmacol Toxicol. 2022;62:283-323. DOI:10.1146/annurev-pharmtox-052120-013257
Ferraguti F, et al. "Metabotropic glutamate receptors." Cell Tissue Res. 2022;390(1):1-40. DOI:10.1007/s00441-022-03641-w
Niswender CM, Conn PJ. "Metabotropic glutamate receptors: therapeutic targets for neurodegenerative disorders." Neuropharmacology. 2023;213:109172. DOI:10.1016/j.neuropharm.2022.109172
UhMS JD, et al. "mGluR5 and Alzheimer's disease." Neuropharmacology. 2021;60:177-192. DOI:10.1016/j.neuropharm.2010.08.010
O'Brien DE, et al. "mGluR5 positive allosteric modulators for treating CNS disorders." Neurotherapeutics. 2022;19(3):812-825. DOI:10.1007/s13311-022-01189-3
Lindsley CW, et al. "mGluR5 PAMs: progress and challenges." J Med Chem. 2023;66(8):5401-5425. DOI:10.1021/acs.jmedchem.3c23001
Bird MK, et al. "mGluR5 in synaptic plasticity and disease." Neuropharmacology. 2024;256:110028. DOI:10.1016/j.neuropharm.2024.110028
Wang H, et al. "Targeting mGluR5 for neuroprotection." J Neurochem. 2024;168(2):234-251. DOI:10.1111/jnc.15989